Robert W. Baird initiated coverage on Omada Health with a new price target
$OMDA
Medical/Nursing Services
Health Care
Robert W. Baird initiated coverage of Omada Health with a rating of Neutral and set a new price target of $24.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/5/2025 | $24.00 | Neutral | Robert W. Baird |
| 7/1/2025 | $21.00 | Outperform | Evercore ISI |
| 7/1/2025 | $25.00 | Overweight | Morgan Stanley |
| 7/1/2025 | $19.00 | Overweight | Analyst |
| 7/1/2025 | $23.00 | Buy | Needham |
| 7/1/2025 | $21.00 | Overweight | Barclays |
| 7/1/2025 | $29.00 | Buy | Goldman |
| 7/1/2025 | $27.00 | Buy | Canaccord Genuity |
SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s,1 challenging widespread assumptions of inevitable post-medication weight regain. Since the GLP-1 Care Track launched, Omada has supported more than 100,000 members taking GLP-1 medications. The retrospective analysis included 816 members in Omada's GLP-1 Care Track and examined GLP-1 discontinuation and subsequent weight change at 6, 9, and 12 months.1 At one year post-discontinuation members showed just 0.8% ave
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data¹ demonstrating that patients who used Omada's virtual physical therapy (PT) program to address musculoskeletal (MSK) conditions, Omada for Joint & Muscle Health, had lower utilization of total medical care and reduced MSK-related costs and encounters on average at 6 and 12 months compared to patients who used in-person PT (IP-PT). This study is believed to be one of the first peer-reviewed healthcare claims analyses to compare costs and utilization of virtual PT (V-PT) and IP-PT in treating MSK conditions while also accounting for the cost of the vir
SAN FRANCISCO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference, taking place in New York, including a fireside chat on Tuesday, September 9, 2025, at 5:35 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events. A replay will also be available at the same link following the event. About Omada Health Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavi
Robert W. Baird initiated coverage of Omada Health with a rating of Neutral and set a new price target of $24.00
Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00
Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00
SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)
SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)
10-Q - Omada Health, Inc. (0001611115) (Filer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s,1 challenging widespread assumptions of inevitable post-medication weight regain. Since the GLP-1 Care Track launched, Omada has supported more than 100,000 members taking GLP-1 medications. The retrospective analysis included 816 members in Omada's GLP-1 Care Track and examined GLP-1 discontinuation and subsequent weight change at 6, 9, and 12 months.1 At one year post-discontinuation members showed just 0.8% ave
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data¹ demonstrating that patients who used Omada's virtual physical therapy (PT) program to address musculoskeletal (MSK) conditions, Omada for Joint & Muscle Health, had lower utilization of total medical care and reduced MSK-related costs and encounters on average at 6 and 12 months compared to patients who used in-person PT (IP-PT). This study is believed to be one of the first peer-reviewed healthcare claims analyses to compare costs and utilization of virtual PT (V-PT) and IP-PT in treating MSK conditions while also accounting for the cost of the vir
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l